Naloxone potentiation of 2-Br-alpha-ergocryptine (CB 154) effects on GH secretion in man.
The effect of the combined administration of either CB 154 (2.5 mg/osM) or L-DOPA (500 mg/osM) and naloxone have been studied in six normal male volunteers. Naloxone cause a clear-cut potentiation of CB 154 effects on human growth hormone (hGH) secretion and only a slight, statistically non-significant, potentiation of L-DOPA effects on hGH secretion. These results have been discussed in the light of morphofunctional findings showing possible interactions between dopamine (DA) systems and somatostatin-positive and enkephalin-positive nerve terminals.
D000328:Adult; D001971:Bromocriptine / Q000008:administration & dosage* / Q000494:pharmacology; D004357:Drug Synergism; D005246:Feedback; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage; D008297:Male; D009270:Naloxone / Q000008:administration & dosage* / Q000494:pharmacology; D011954:Receptors, Dopamine / Q000502:physiology*; D011957:Receptors, Opioid / Q000502:physiology*
D011954:Receptors, Dopamine; D011957:Receptors, Opioid; D009270:Naloxone; D001971:Bromocriptine; D007980:Levodopa; D013006:Growth Hormone